INTRODUCTION
Respiratory syncytial (RS) virus is unique among respiratory pathogens because of its predilection for causing serious lower respiratory tract disease in infants, and because it is a monotypic virus whose structural proteins have unusual characteristics. RS virus causes the largest fraction of pneumonia and bronchiolitis among infants and children under 4 years of age, and especially among those between 2 and 6 months of age (Chanock et al., 1976; Belshe et al., 1984) . In temperate climates, epidemics of RS virus occur annually in the winter and spring months, spread widely in the community, and are associated with high rates of respiratory tract disease requiring hospitalization (Parrott et al., 1973; Glezen et al., 1981) . In the youngest age groups, pneumonia and bronchiolitis develop in the presence of maternally derived antibody (Lamprecht et al., 1976) , and re-infection associated with mild respiratory illness occurs also in the adult despite the presence of neutralizing antibody (Johnson et al., 1962; Henderson et al., 1979) . The immunological basis for these findings has not been elucidated.
The observed high frequency and seriousness of lower respiratory tract disease in infants and children under 1 year old who possess neutralizing antibody might result from an antigenantibody interaction in the lungs. This explanation has been suggested on the basis of results from an inactivated vaccine trial (Kapikian et al., 1969; Kim et al., 1969; Chanock et al., 1970; Mclntosh & Fishaut, 1980) . A few children immunized with a parenteral inactivated and concentrated RS virus vaccine became more seriously ill after subsequent natural infection with RS virus than did those children who received placebo vaccine. In later studies of naturally occurring illness, however, maternally transferred neutralizing antibody was shown to moderate isolation) were WV1293 (1979 ), WV3212 (1980 , WV4843 (1981) , WV6873 (1982) , WV9894 (1983) and WV12138 (1984) ; each was re-isolated in H Ep-2 cells, then passaged once or twice in Vero cells and used as seed material for strain analyses. The seventh RS virus strain (CH287) was recovered from a child at the Children's Hospital, Washington, D.C., U.S.A. (Buynak et al., 1978) ; it was re-isolated and passaged twice in grivet monkey kidney cells, then ten times in human diploid fibroblast cells (WI38). Previously, CH287 has been administered to volunteers as a parenteral live virus vaccine (Belshe et al., 1982) . For strain analyses, it was passaged three further times in HEp-2 cells and twice in Vero cells. The prototype RS virus strains were Long and A2; these were passaged in Vero or in HeLa cells.
Cells. Vero and HeLa cells were grown in Eagle's MEM supplemented with 5 ~ foetal calf serum (FCS) which had been inactivated by heating at 56 °C for 30 rain. When nearly confluent monolayers were obtained, the cells were maintained on medium with 1 ~ FCS.
Production ofhybridoma celllines. Extracellular virions were purified from medium of Vero cell cultures infected with the Long strain of RS virus. The purification procedure included banding in a sucrose gradient as described previously for mumps virus (0rvell, 1978) . The purified virions at a protein concentration of 0.5 to 1-0 mg/ml were mixed with an equal volume of Freund's complete adjuvant and 0.4 ml was injected intramuscularly into each hind leg of BALB/c mice. Two to 4 months later the animals were given booster injections and their spleen cells were used for establishment of hybridoma cell lines by a method described previously (Orvell & Grandien, 1982) . Most fusions were performed with the myeloma cell line SP2/0. Production of specific antibodies by hybridoma cells was screened by ELISA using RS virus-infected Vero cells as antigen. Cells infected with another paramyxovirus were used as a control.
Neutralization and cell fusion inhibition tests. Neutralizing antibodies were determined by endpoint determination on Vero cells in microplate wells with serial twofold dilutions of inactivated (56 °C, 30 min) ascites fluid mixed with 100 tissue culture infectious doses of RS virus. Details of the technique have been given previously (Togashi et al., 1981) . The capacity of monoclonal antibodies to inhibit virus-induced cell fusion was determined by inoculation of Vero cell monolayers in microtitre plate wells with virus at a multiplicity of about 0.05. After incubation with gentle rocking of the plate for 2 h at 37 °C, the inoculum was discarded and medium containing serial twofold dilutions of inactivated ascites fluid was added. Two days later the cultures were inspected for the occurrence of syncytia. The highest dilution of ascites that completely prevented syncytium formation was taken as the endpoint.
lmmunefluorescenee analysis. The technique of immunofluorescence has been described previously (Norrby et al., 1982) . Semiconfluent monolayers of Vero or HeLa cells on glass slides were inoculated with virus at a m.o.i, of about 0.1. After 2 to 3 days the glass slides were fixed in cold (-20 °C) acetone for 10 min and then air-dried. The preparations were stored at -70 °C. Ascites fluids were tested at a dilution of 1/20. A fluorescein-conjugated goat anti-mouse Ig (Dakopatts, Copenhagen, Denmark) was employed at a dilution of 1/15.
Radioimmunoprecipitation assay (RIPA) . Both Vero and HeLa cells were infected with seed material and intracellular viral antigens were labelled with [35S]methionine or [3 H]glucosamine for 24 h prior to development of extensive cytopathic effects. Cells were scraped into the supernatant, pelleted, washed twice with cold phosphatebuffered saline, and dissolved on ice with a buffer containing 2~ Triton X-100, 0.15 M-NaC1, 0.6 M-KC1, 0.5 mMMgC12, 1 mr, i-phenylmethylsulphonyl fluoride (PMSF) and 1 ~ trasylol aprotinin (TA) in 0-01 M-Tris-HCI pH 7-8. The supernatant was collected, clarified in an Eppendorf centrifuge and then stored at -20 °C until used. The antigen preparation was precipitated with monoclonal antibodies and fractionated by SDS-polyacrylamide gel (12-5 ~) electrophoresis (PAGE) under reducing conditions. The details of the procedures used were described previously (Orvell & Norrby, 1980; Sheshberadaran et al., 1983) .
Competition experiments by use of peroxidase-conjugated monoclonal antibodies in enzyme-linked immunosorbent assay (EL1SA). The methods used here were similar to those described in detail previously for experiments with Sendai and mumps viruses (Orvell & Grandien, 1982; Orvell, 1984) . Homologous non-labelled ascites and ascites from mice inoculated with SP2/0 myeloma cells were used as positive and negative controls, respectively. All wells of plastic plates used in competition experiments were coated with 0-1 ml of purified RS virions at a final concentration of 20 gg/ml.
RESULTS

Monoclonal antibodies against RS virus
A collection of 31 RS virus-specific monoclonal antibodies were used in this study (Tables 1 to  4 ). Antibody-containing ascites fluids had ELISA titres of 103 to 106. Different IgG subclasses were represented, with IgG1 predominating. No IgM monoclonal antibodies were used in the study. The specificity of the antibodies was determined by RIPA tests (Fig. 1) . Five different specificities were distinguished. The character of the precipitated proteins has been identified previously (Peeples & Levine, 1979; Gruber & Levine, 1983; Walsh & Hruska, 1983; Collins et al., 1984b) . * A + means that the ELISA titre of a given antibody was reduced by a factor of 103 or more, whereas aindicates the absence of such a competition at a 1 : 10 dilution of ascites fluid. Fig. 2 ). None of the antibodies against the G protein could neutralize the virus or block virus-induced cell fusion.
Six antibodies precipitated the 48K plus 19K F protein ( Fig. 1 , Table 2 ). These antibodies also precipitated some 95K to 100K undissociated F material (see also Fig. 2) ; this was interpreted to represent undissociated F material since only a high tool. wt. band was observed under nonreducing conditions and it was not precipitated from labelled uninfected control cell lysates. These proteins were also heavily labelled by [3H]glucosamine (Fig. 2) . One of the F-specific antibodies (no. B151) could neutralize the virus and inhibit virus-induced cell fusion; the endpoint titres were 2560 and 80, respectively. Immunofluorescence analysis with antibodies against the viral glycoproteins showed diffuse staining of cells with some accumulation in the cytoplasmic membrane as described previously Walsh & Hruska, 1983) .
Six, nine and one antibodies precipitated the 26K M (Table 3) , the 41K NP (Table 4 ) and the 36K P proteins, respectively. The latter antibody also precipitated some breakdown products of the protease-sensitive P protein and co-precipitated some 41K NP material ( Fig. 1 to 3) . No proteolytic degradation of P was seen in RIPA performed with P-specific monoclonal antibodies in the study by Gimenez et al. (1984) . This may be due to differences in the compositions of the lysis buffers used. None of these antibodies could neutralize virus or block virus-induced cell fusion. In immunofluorescence experiments, antibodies against the NP and P proteins stained rounded cytoplasmic inclusions of various sizes in accordance with previously published data Walsh & Hruska, 1983) . Monoclonal antibodies against M gave a more diffuse staining pattern (data not shown).
Epitope characterization of different structural components by use of peroxidase-conjugated monoclonal antibodies in ELISA
Monoclonal antibodies directed against the G, F, M and N P components were labelled with peroxidase and used in competition experiments with available antibodies against the homologous component. Totals of six, two, six and six different epitopes were identified on the Tables 1 and 2 ). (Tables 1 to 4 ). The results of these experiments showed that in the panel of antibodies directed against the NP and M protein, antibody against a particular epitope was blocked in most cases by only a few of the antibodies directed against other epitopes (Tables 3 and 4 ). In contrast, antibody directed against a particular epitope of the G protein was blocked in most cases by a majority of the antibodies specific for the five other epitopes (Table 1) . Nevertheless, six (or possibly seven) different reaction patterns were discernible. Antibodies against the F protein showed only two different competition patterns (Table 2) . Five antibodies efficiently blocked the binding of each other to this protein, but were not blocked by antibody B 151. Reciprocally, antibody B 151 was not blocked by any antibodies within the group of five.
Comparison of virus strains by RIPA tests and immune fluorescence analysis
Each of the seven RS virus field strains were reacted with the panel of 31 monoclonal antibodies. Two different and distinct patterns of reactivity emerged which could be used to divide the strains into two subtypes, designated A and B (Table 5 ). The A designation was given to strains that had a character similar to the prototype strains because the latter were isolated first. The major differences in reactivity involved the 90K G glycoprotein, but the F, M and NP proteins also showed certain divergent characteristics.
In RIPA, the four strains of the B subtype, WV1293, WV3212, WV4843 and WV6873, reacted with only one anti-G antibody, C793 (epitype G1), and only when grown in HeLa cells, in contrast to the three field isolates of the A subtype, WV9894, WV 12138 and CH287 (Vero or HeLa cell-grown), which were positive with all nine anti-G antibodies, as were both the A2 and Long prototype strains (Table 5 ; Fig. 2 a, b) . The results were identical by immunofluorescence. The subtype A strains were positive with all six anti-F antibodies, representing two epitypes, both in RIPA and immunofluorescence. Two subtype B strains failed to react with two anti-F antibodies, C787 and B81, in RIPA but not in immunofluorescence (Table 5 , Fig. 2a, b) . The 
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difference in reactivity by RIPA and immunofluorescence suggests that the epitope detected by these two antibodies is lysis buffer-sensitive in subtype B strains, but not in subtype A strains (see also Orvell & Norrby, 1985) . The fact that C787, B81 and three other antibodies appear to react in competition ELISA with the same epitope reflects the limitation in detection of small differences by this test. A similar situation has been encountered in studies of measles virus H protein (H. Sheshberadaran & E. Norrby, unpublished results).
All subtype A strains were positive with all anti-M antibodies both in RIPA and immunofluorescence (Table 5 , Fig. 3a, b) . Anti-M antibodies C785 and B135 failed to react in RIPA with one and four of the subtype B strains, respectively, but these antibodies were positive by immunofluorescence. Thus, these epitopes are lysis buffer-sensitive also. Interestingly, C785 antibodies were positive in immunofluorescence tests with subtype B strains grown only in HeLa cells, not with those in Vero ceils. Similar differences depending upon host cells have been described for influenZa virus (Schild et al., 1983) . The subtype A strains were uniformly positive with all anti-NP antibodies, by RIPA and immunofluorescence. However, all four subtype B strains were unreactive with two anti-NP antibodies, C3222 and B90, both of epitype NP1, whereas the subtype B strains reacted with all other anti-NP antibodies (Table 5 , Fig. 3a, b) . Anti-NP antibody C3222 was negative by RIPA and positive by immunofluorescence with the subtype B strains, suggesting that this epitope is also lysis buffer-sensitive. The third antibody of epitype NP1, C797, reacted with both subtype A and B strains, both in RIPA and immunofluorescence and reflects the potential variability that can occur among antibodies of the same epitype as defined by competition ELISA.
Strains of subtype B were isolated in Huntington, West Virginia during epidemics in successive years from 1979 to 1982. The two subtype A strains from Huntington were isolated during 1983 and 1984, and the subtype A strain from Washington, D.C. was isolated during 1973. Although only one strain was tested from each of these epidemic years, occurrence of two subtypes of RS virus over such long times provides evidence of their stability.
DISCUSSION
The present study shows that RS virus strains can be divided into two groups representing distinct subtypes, here named A and B. The main difference between the subtypes was observed in the G protein, which showed a sharing of only one of six epitopes. Differences were also detected within one epitope on the F protein, in two epitopes on the M protein and within one epitope on the NP component. These pronounced differences make it clear that the phenomenon observed does not represent the kind of strain variation observed in for example the H component of monotypic measles virus which involves single epitopes and reflects occasional mutational events (Sheshberadaran et al., 1983) . Further, these differences most likely do not represent a recombination event between for example a human and an animal virus as seen in antigenic shift by genetic reassortment of influenza A viruses. Aside from the fact that such an event is extremely unlikely to occur in a linear negative-strand RNA virus, it would be difficult to explain the concomitant changes in many structural components by this mechanism. Therefore, it would seem that the two subtypes of RS virus have evolved separately for a considerable time period. Preliminary data show that the F1 protein of subtype B strains has a somewhat lower molecular weight than the corresponding protein of subtype A strains (M. A. Mufson et al., unpublished results). Previously it has been shown that the molecular weight of the P protein shows some variation between strains (Cash et al., 1977) . The possible occurrence of structurally identifiable differences between the two subtypes needs to be further evaluated and polyclonal antisera should be employed to identify the degree of cross-neutralization between RS virus subtype A and B strains.
The discovery of two stable subtypes does not exclude the possible existence of more subtypes. The isolates made during the years 1979 to 1982 (WV1293, WV3212, WV4843, WV6873) represent the same subtype, denoted B. Members of the other subtype, A, were isolated both before (laboratory strains Long and A2, vaccine strain CH287) and after this period, in 1983 and 1984 (isolates WV9894 and WV12138) . The strain 18537 which was shown to differ from the prototype strain A2 by Coates et al. (1963) is probably of subtype B (E. Norrby et al., unpublished results) . It is obviously of importance to evaluate whether infection with one subtype provides immune protection against the second subtype and, if this is the case, the durability of this protection.
Studies of other paramyxoviruses have shown that the HN (or H in morbilliviruses) component is primarily involved in interaction with antibodies that give direct neutralization in vitro (see t3rvell . Although antibodies against the F protein have no or only a weak neutralizing capacity in vitro [an exception being simian virus 5 (Merz et al., 1980) ], they play an important role in protection against disseminating infection in vivo (Norrby et al., 1975 ; Orvell & Norrby, 1977; Merz et al., 1980; Orvell & Grandien, 1982) . The two glycoproteins of RS virus are different in that both are involved in neutralization in vitro (Walsh & Hruska, 1983; Walsh et al., 1984a) . In fact the F protein may even play a somewhat greater role than the G protein, judging from the relative occurrence of neutralizing monoclonal antibodies among those which react with each of these components . In passive transfer experiments with monoclonal antibodies against each of the glycoproteins, no difference could be observed in their capacity to restrict RS virus replication in lung tissues of cotton rats (Walsh et al., 1984b) and in mice (Taylor et al., 1984) .
The fact that the two subtypes of RS virus with similar F glycoproteins also share a neutralizing epitope, but have very different G glycoproteins, makes it possible to explain the early findings of strain differences in cross-neutralization tests with animal hyperimmune sera (Coates et al., 1963 ; Wulff et al., 1964; Doggett & Taylor-Robinson, 1964) . The low level crossreactions seen between some strains most likely represent the effect of antibodies against a closely related F protein in viruses of each of the two subtypes.
The consequences of the occurrence of two (or more) subtypes has implications for (i) the occurrence of infections with RS virus in the presence of maternal antibodies, (ii) the recurrence of infections with RS virus, and (iii) the failure to date to produce an effective RS vaccine.
Passively transferred maternal antibodies have been shown to exert a mitigating effect on RS virus infection (Parrott et al., 1973; Lamprecht et al., 1976; Glezen et al., 1981) . However, the important question now concerns how effectively maternal antibodies against one subtype can protect a child exposed to a second subtype. Immunization of experimental animals with isolated G and F glycoproteins of each subtype of virus could be performed in order to evaluate the protective efficacy of humoral immunity against the heterologous subtype. Ward et al. (1983) found that young children mobilized a relatively weak antibody response to the G protein. One possible explanation for this finding could be subtype differences between the virus strain infecting the children and the strain used in the RIPA test.
Recurrent infections may be influenced not only by humoral, but also by cell-associated immunity derived from prior infection(s) with RS virus. Also, in this situation it is important to evaluate the protective effects of infection with one subtype on subsequent exposure to virus of a second subtype. The consequence of consecutive infections with the two subtypes could be analysed in experimental animals.
Attempts to develop RS virus vaccines have not met with success. In the first trials, a formalin-inactivated vaccine was tested. However, the 'immunity' established did not protect; instead it probably formed the basis for a more frequent and more severe respiratory tract involvement in vaccinated individuals than in their unvaccinated counterparts when they were infected with RS virus during the subsequent season (Kapikian et al., 1969; Kim et al., 1969) . In attempts to explain this state of hyper-reactivity, analogies have been drawn with the condition of children contracting atypical measles after immunization with a formalin-inactivated vaccine. In this case, it was shown that destruction of crucial immunogenic properties of the measles virus F protein allowed virus replication (Norrby et al., 1975; Merz et al., 1980) . Sensitization to H antigen prior to exposure was presumably the explanation for the observed immune pathological complications. Although similar phenomena may be relevant in the case of RS virus, the occurrence of subtypes of the virus differing in G protein immunogens makes the interpretation of sensitization events in vaccinated subjects more complex. The abovementioned cross-protection experiments with related glycoproteins may aid in designing the appropriate inactivated vaccine. Most likely it will be necessary to include G proteins representing different subtypes in addition to F protein in order to provide an effective vaccine. The need to protect against different subtypes must be similarly considered when attempts are made to develop live virus vaccines.
During the preparation of this manuscript it came to our notice (E. J. Stott, personal communication) that the occurrence of two subtypes of RS virus has been discovered in studies at the AFRC Institute for Research on Animal Diseases, Compton, Newbury, U.K. A number of RS virus isolates made during the same season in Bristol, U.K. were examined with a panel of monoclonal antibodies different to those used in this study. A major variation in G protein and a minor variation in F protein was observed, similar to the present findings.
After submission of this report for publication, two articles (Anderson et al., 1985; Prince et al., 1985) describing results of relevance to the present findings appeared. Anderson et al. (l 985) used 23 monoctonal antibodies against the G, F and NP components of the Long, A2 and 18537 strains to examine 16 RS virus strains. The strains could be divided into three groups. Group 2 which included strain 18537 showed more distinct antigenic properties than the other groups which included the A2 and Long prototype strains. The division into subtypes A and B in the present study parallels this observation. The investigation by Prince et al. (1985) showed that antigenic heterogeneity reflected by different behaviour of strains in neutralization tests in vitro may not be reflected by differences when the strains are examined for cross-protection in vivo. However, a possible role of surface antigen differences among RS virus strains in the development of immune pathological phenomena deserves further study.
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